# ONCOCROSS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncocross

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.oncocross.com
- Total disclosed funding: $19M
- Latest round: Series B (Sep 29, 2020)
- Investors on record: 15

## About

Based in South Korea, ONCOCROSS develops innovative AI-driven therapies targeting unmet medical needs in oncology and rare diseases, utilizing advanced technology to enhance drug discovery.Founded in 2015, ONCOCROSS is focused on innovative drug development through artificial intelligence. The company is headquartered in Seoul, South Korea, and has successfully completed a total of 8 deals. Recently, ONCOCROSS raised KRW 10.4 billion in a PRE-IPO round on December 18, 2024, with investments from Dongwha Pharmaceutical, InterVest, Moru Asset Management, Pathfinder H, and ST Capital, bringing the total amount raised to KRW 14.5 billion and achieving a company valuation of KRW 123,728.87 million. The CEO is Yi-rang Kim.ONCOCROSS specializes in innovative drug development using artificial intelligence to meet medical needs, especially in oncology and rare diseases. Their flagship offerings include the ONCOCROSS AI Platform, featuring proprietary tools such as RAPTOR AI™, ONCO-RAPTOR AI™, and ONCOfind AI™, which leverage transcriptomic data to optimize drug efficacy and identify potential biomarkers. The company collaborates with pharmaceutical partners and research institutions worldwide, focusing on enhancing the drug development process and significantly reducing timelines for new treatments.In 2023, ONCOCROSS generated revenue amounting to KRW 70,108.3 million. The company reported an EBITDA of KRW -4,880,685.1 million during the same period. Revenue is primarily generated through partnerships with pharmaceutical companies and research institutions, involving licensing of their AI-driven drug discovery technologies and access to medical databases.ONCOCROSS plans to leverage its recent funding from the PRE-IPO round to accelerate the development of new products and enhance its AI platforms. The company aims to expand its market presence particularly in North America and Europe by 2025. The funds raised will support the launch of new innovative tools and continued partnerships with pharmaceutical firms, enhancing their collaborative drug development capabilities.

## Funding rounds

- Series B, Sep 29, 2020, $14M — KDB Capital, Smilegate Investment, G.N.TECH Venture Capital, Hanbit Investment Corporation, ID Ventures, Wooshin Venture Capital, NAU IB Capital, Magna Investment, LS Securities, Vision Creator, KB Securities
- Series A, May 25, 2019, $5.1M — Smilegate Investment, G.N.TECH Venture Capital, Hanbit Investment Corporation, ID Ventures, Wooshin Venture Capital, Hana Securities, SM-Sino Technology Investment
- Seed, Nov 1, 2018, $0.3M — Korea Tech Incubator for Startup, Kingsley Ventures

## Investors

- Korea Tech Incubator for Startup — Seed
- Kingsley Ventures (https://capitalatlas.ai/funds/kingsley-ventures) — Seed
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A, Series B
- G.N.TECH Venture Capital (https://capitalatlas.ai/funds/g-n-tech-venture-capital) — Series A, Series B
- Hanbit Investment Corporation (https://capitalatlas.ai/funds/hanbit-investment-corporation) — Series A, Series B
- ID Ventures (https://capitalatlas.ai/funds/id-ventures) — Series A, Series B
- Wooshin Venture Capital (https://capitalatlas.ai/funds/wooshin-venture-capital) — Series A, Series B
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series A
- SM-Sino Technology Investment (https://capitalatlas.ai/funds/sm-sino-technology-investment) — Series A
- KDB Capital (https://capitalatlas.ai/funds/kdb-capital) — Series B
- NAU IB Capital (https://capitalatlas.ai/funds/nau-ib-capital) — Series B
- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series B
- LS Securities — Series B
- Vision Creator — Series B
- KB Securities (https://capitalatlas.ai/funds/kb-securities) — Series B